Bioneer Inc., established in 1992, is a pioneering South Korean biotechnology company. It focuses on developing and manufacturing innovative products and technologies for molecular biology, molecular diagnostics, and RNAi-based therapeutics. Bioneer's portfolio includes automated nucleic acid extraction systems, real-time PCR diagnostic kits, gene synthesis services, oligonucleotides, enzymes, and probiotics. The company is committed to advancing human health and scientific research through its cutting-edge biotechnological solutions, serving researchers, clinicians, and industrial partners globally.
The headquarters serves as the primary center for Bioneer's research and development, advanced manufacturing of biotechnology products (including molecular diagnostic kits and instruments), and global corporate management.
Features state-of-the-art R&D laboratories, GMP-compliant manufacturing facilities for diagnostics and therapeutics, and automated production lines for molecular biology reagents.
Characterized by a strong emphasis on innovation, scientific rigor, and collaboration. Bioneer fosters a dynamic environment for research scientists and engineers dedicated to biotechnological advancements.
Strategically located in Daedeok Innopolis, South Korea's premier science and technology hub, facilitating access to talent, research collaborations, and industry partnerships.
Bioneer Inc. maintains a significant global presence with operations and a distribution network spanning Asia, North America, Europe, and other key international markets. Through its subsidiaries (USA, China, Germany) and extensive network of distributors, Bioneer provides its molecular biology products, diagnostic systems, and custom services to researchers, clinicians, and industries worldwide. This global footprint supports international sales, customer service, technical support, and collaborative research initiatives.
8-11 Munpyeongseo-ro, Daedeok-gu
Daejeon
Daejeon
Republic of Korea
Address: 1301 Marina Village Pkwy, Suite 110, Alameda, CA 94501, USA
To directly serve and expand Bioneer's customer base in the United States, a significant market for biotechnology and life science research, ensuring localized support and product availability.
Address: 4F, Building C6, No.116, Haiyuan Road, TEDA, Tianjin, 300457, China
To cater to the rapidly growing demand for biotechnology tools, diagnostic products, and research reagents in China's life science and healthcare industries.
Address: IZB, Am Klopferspitz 19a, D-82152 Planegg, Germany
To strengthen Bioneer's market presence in the European Union, offering localized services and facilitating access to its advanced biotechnological solutions for European researchers and diagnostic labs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Bioneer' leadership includes:
Bioneer has been backed by several prominent investors over the years, including:
No major publicly announced executive hires or exits at Bioneer Inc. have been identified in widespread English-language media over the last 12 months. Significant leadership changes are typically communicated through official investor relations channels or regulatory filings in its domestic market.
Discover the tools Bioneer uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Bioneer Inc. likely utilizes standard corporate email address formats. Common patterns for companies in the biotechnology sector include combinations of first name, last name, and initials.
flast@bioneer.com (e.g., hpark@bioneer.com)
Format
hpark@bioneer.com
Example
75%
Success rate
BusinessKorea • May 20, 2024
Bioneer Inc. announced an agreement to supply essential materials for Lipid Nanoparticle (LNP) drug delivery systems to a U.S. biotechnology firm. This deal underscores Bioneer's expertise in producing high-quality components for advanced therapeutic delivery technologies....more
The Korea Herald • February 20, 2024
Bioneer Inc. reported promising preclinical trial results for its RNAi-based therapeutic candidate, SAMiRNA-AREG. The drug demonstrated efficacy in animal models for treating obesity and non-alcoholic steatohepatitis (NASH), indicating its potential as a future treatment....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Bioneer, are just a search away.